论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Tang P, Xu P, Shu W, Wang X, Guo J, Song H, Li S, Pang Y, Wu M
Received 24 July 2018
Accepted for publication 5 December 2018
Published 27 December 2018 Volume 2019:12 Pages 87—93
DOI https://doi.org/10.2147/IDR.S181259
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 4
Editor who approved publication: Professor Suresh Antony
Background: We performed a
prospective study to investigate the association between pre-diagnosis exposure
to fluoroquinolone (FQ) and laboratory testing results among tuberculosis (TB)
patients.
Patients and methods: Each
TB-suspected patient provided sputum specimen for mycobacteria growth indicator
tube (MGIT) culture and GeneXpert among pulmonary TB patients. Confirmed TB
patients and clinically diagnosed TB patients were further enrolled in the
final analysis.
Results: A total of 661
TB patients were included in the final analysis. The distribution of rural TB
patients in the FQ-exposed group was significantly higher than that of urban TB
patients (P =0.02).
GeneXpert showed significantly better positive rate than MGIT technology for TB
cases with prior FQ exposure (30.6% for GeneXpert vs 20.1% for MGIT, P =0.01). The
positive rate of GeneXpert was significantly higher than that of MGIT for 7–13
days (P =0.04)
and ≥14 days FQ exposure (P =0.01) groups, respectively. We also found that the
positive rate of MGIT was significantly decreased from 31.5% for <7 days
levofloxacin (LFX) exposure group to 9.4% for ≥14 days LFX exposure group (P =0.01), whereas
the positive rate of MGIT displayed significant decrease after 7–13 days
exposure to moxifloxacin (P =0.04).
Conclusion: In conclusion,
our data demonstrate that TB patients prior to sputum collection are prone to
yield negative culture results. GeneXpert could bring additional benefits for
the detection of pulmonary TB patients with prior exposure to FQs. In addition,
the exposure to moxifloxacin affected mycobacterial culture at an earlier stage
compared with LFX.
Keywords: tuberculosis,
fluoroquinolone exposure, GeneXpert